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Abstract
Background/Aims: Nutritional status is a factor affecting 
prognosis in patients with amyotrophic lateral sclerosis 
(ALS). Here, we aimed to clarify the factors associated with 
hypermetabolism and the prognosticators of ALS. Methods: 
Forty-two inpatients (22 men, 20 women) diagnosed with 
ALS according to the revised El-Escorial criteria were investi-
gated. The following data were retrospectively analyzed: an-
thropometric measurements, blood biochemistry, disease 
severity, basal energy expenditure (BEE), resting energy ex-
penditure (REE) measured by indirect calorimetry, spirome-
try, and bioelectrical impedance analysis. Single and multi-
ple regression analysis was performed to examine factors af-
fecting REE and metabolic changes (defined as the ratio of 
REE to fat-free mass [FFM]). The Kaplan-Meier method was 
used to examine factors associated with the occurrence of 
cumulative events (death or tracheostomy). Results: Among 
the 42 inpatients, REE was significantly higher than BEE, indi-
cating hypermetabolism in ALS. Multiple regression analysis 
revealed that REE/FFM is strongly associated with the skele-
tal muscle index (−3.746 to −1.532, p < 0.0001) and percent 
forced vital capacity (%FVC) (−0.172 to −0.021, p = 0.013). 
Moreover, both the skeletal muscle index and %FVC were 
significant prognosticators associated with the occurrence 
of cumulative events. Conclusions: Energy metabolism was 
elevated in ALS, and respiratory status and muscle mass were 
associated with the hypermetabolism and poor prognosis. 
Adequate nutritional support may improve outcomes in ALS 
by preventing deterioration of respiratory status and reduc-
tion in muscle mass. © 2021 The Author(s).
Published by S. Karger AG, Basel
Introduction
Amyotrophic lateral sclerosis (ALS) is a fatal paralytic 
disorder with a longevity of 2–4 years unless mechanical 
ventilation is introduced [1, 2]. Various clinical features 
of ALS affect the prognosis of the disease. Previously re-
ported prognostic factors of ALS include bulbar palsy [3, 
4], respiratory muscle disorder/injury [5], older age at on-
set [3, 6, 7], malnutrition at diagnosis or during the dis-
This article is licensed under the Creative Commons Attribution 4.0 
International License (CC BY) (http://www.karger.com/Services/
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ease course [8, 9], low body mass index (BMI) [10], Re-
vised Amyotrophic Lateral Sclerosis Functional Rating 
Scale (ALSFRS-R) score [11, 12], and percent forced vital 
capacity (%FVC) [12–14]. Above all, recent evidence 
shows the presence of elevated energy metabolism [15–
19] in ALS, which underlies the body weight reduction 
seen in the disease, as well as insufficient energy intake 
[2]. Notably, early nutritional intervention with a high 
calorie diet significantly improves prognosis [1, 2]. How-
ever, how hypermetabolism exacerbates the clinical 
course of ALS is still unclear.
On the other hand, the respiratory muscle weakness 
that occurs with ALS progression results in decreased 
ventilation volume, labored respiration, and increased re-
spiratory rate, and this decline in respiratory status has 
been shown to be associated with increased energy me-
tabolism [20, 21]. Moreover, upon further deterioration 
of respiratory function, the burden on the respiratory 
muscles can be reduced by tracheostomy-positive pres-
sure ventilation, which decreases energy metabolism 
[22]. Therefore, it is necessary to elucidate the role of en-
ergy metabolism in respiratory function during the clini-
cal course of ALS.
Evaluating energy requirement in ALS is crucial but 
also difficult due to confounding factors such as obesity, 
sex, and ethnicity. Based on the insufficient energy ex-
penditure calculated using the Harris-Benedict equation 
[23], Shimizu and colleagues [24] proposed a standard 
formulation to estimate the total energy expenditure 
(TEE) of Japanese ALS patients, which uses ALSFRS-R, 
age, body weight, and height. Another convenient meth-
od for estimating an individual’s energy requirement is to 
use the resting energy expenditure (REE) determined by 
indirect calorimetry. To assess energy metabolism, REE 
alone cannot be used as a strict marker of metabolic 
changes because it has been shown to correlate strongly 
with body composition, especially fat-free mass (FFM). 
Therefore, FFM-adjusted REE (REE divided by FFM) 
[25] has become an accepted indicator for assessing met-
abolic changes. In this study, we retrospectively analyzed 
indirect calorimetry, body composition, and spirometry 
in 42 hospitalized ALS patients to ascertain the factors 
involved in energy metabolism and prognosis.
Materials and Methods
Patients and Ethical Considerations
We retrospectively collected cases of patients with ALS accord-
ing to the revised El-Escorial criteria who had been admitted to 
Shiga University of Medical Science Hospital from March 2018 to 
May 2020 and who did not use a respirator and had undergone 
indirect calorimetry, body composition analysis, and spirometry. 
A total of 42 patients (22 men and 20 women) were enrolled in 
this study. Among them, 36 patients were admitted for diagnostic 
reasons and 6 patients were admitted for percutaneous endoscop-
ic gastrostomy placement, which was performed due to dyspha-
gia. All clinical parameters were collected before percutaneous en-
doscopic gastrostomy placement. None of the patients had infec-
tious diseases or diseases other than ALS that affect energy 
metabolism.
Clinical Parameters
The following anthropometric measurements were obtained 
on admission: height (cm), body weight (BW; kg), and BMI (kg/
m2). Bioelectrical impedance analysis was performed using a body 
composition analyzer (S10®, InBody) to determine FFM (kg), 
body fat (kg), and skeletal muscle index (SMI; kg/m2). The cutoff 
values of SMI for identifying low muscle mass were 7.0 kg/m2 for 
men and 5.7 kg/m2 for women, as proposed by the Japan Society 
of Hepatology [26]. The following biochemical test results were 
extracted 5 days before and 5 days after indirect calorimetry: total 
protein (g/dL), albumin (g/dL), total lymphocyte count (/μL), and 
C-reactive protein (mg/dL).
Neurological Function Assessment
The ALSFRS-R [27] was used to assess neurological function. 
The following 12 measures were rated on a 5-point scale from 0 to 
4, with higher scores indicating more retained function: speech, 
salivation, swallowing, handwriting, cutting food and handling 
utensils, dressing and hygiene, turning in bed and adjusting bed 
clothes, walking, climbing stairs, dyspnea, orthopnea, and respira-
tory insufficiency.
Respiratory Function Assessment
Percent forced expiratory volume in 1 s, tidal volume, and 
%FVC were measured by spirometry. The cutoff for %FVC was set 
at 80%.
Energy Metabolism
Basal energy expenditure (BEE) was estimated using the Har-
ris-Benedict equation [23]. REE, carbohydrate oxidation, fat oxi-
dation, and respiratory quotient were measured by indirect calo-
rimetry (Aeromonitor® AE310S, Minato Medical Science Co., 
Ltd.). REE was calculated using the Weir equation without the use 
of urinary nitrogen [28]. Respiratory quotient was calculated as 
carbon dioxide production divided by oxygen uptake (VCO2/
VO2). Indirect calorimetry was performed in the morning after 
the patient had fasted overnight and rested in the supine position 
on a bed for 30 min. The measurements took up to 10 min [29–
32]. Hypermetabolic rate (ΔREE, %) was obtained by dividing 
measured REE by BEE, and metabolic changes due to the disease 
were assessed using the ratio of measured REE to FFM (REE/
FFM). In this study, total energy expenditure (TEE) was estimated 
as the value obtained by multiplying REE by an activity factor 
(REE × AF). AF of 1.2 and 1.3 was used for bed rest and ambula-
tory status, respectively [33]. REE × AF was compared with the 
value obtained using the Shimizu equation [24] and the value ob-
tained by multiplying BEE by an activity factor (BEE × AF). The 
Shimizu equation is a prediction formula based on TEE values 
measured using the doubly labeled water method in 26 Japanese 
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ALS patients and is expressed as follows: TEE (kcal/day) = 1.67 × 
BEE + 11.8 × ALSFRS-R – 680. A predictive formula for REE was 
derived using the data from our cohort, and REE × AF was also 
compared with the values obtained by multiplying predicted REE 
by an activity factor.
Statistical Analysis
All statistical analyses were performed using Prism, version 
8.01 (GraphPad, San Diego, CA, USA), and JMP software, ver-
sion 14.0 (SAS Institute, Cary, NC, USA). The χ2 test and Mann-
Whitney U test were used as appropriate. The Wilcoxon signed 
rank test and the Bland-Altman test were used to compare 
matched pairs. Single and multiple regression analyses were per-
formed to determine factors affecting REE and metabolic chang-
es. Wilcoxon analysis was performed to estimate the risk of 
events (death or tracheostomy). The cumulative event-free sur-
vival rate was calculated using the Kaplan-Meier method. Anal-
ysis was stratified by %FVC, SMI, BMI, and ALSFRS-R. For 
stratification, median values were used for BMI and ALSFRS-R 
and the abovementioned cutoff values were used for %FVC and 
SMI. The Wilcoxon test was used to determine statistical differ-
ences between groups. p values were 2-sided, with statistical sig-
nificance set at p < 0.05.
Results
Patients
A total of 42 patients were included in this study (22 
men and 20 women). Their clinical backgrounds are 
shown in Table 1. Height, BW, and SMI were significant-
ly higher in men than in women, and thus energy me-
tabolism indexes such as BEE and REE were also higher 
in men (Table 1). Also, in this cohort of patients, ΔREE 
was significantly higher in men than women.
Table 1. Background characteristics of the inpatients with ALS in this study
Characteristics All (n = 42) Male (n = 22) Female (n = 20) p value
Age, years 70 (61 to 74) 68 (59 to 74) 73 (63 to 75) 0.230†
BMI 20.2 (18.8 to 22.1) 21.4 (18.9 to 22.2) 19.6 (18.2 to 22.1) 0.420†
Height, cm 160 (154 to 169) 168 (162 to 171) 153 (151 to 156) <0.0001†
Body weight, kg 54 (48 to 61) 58 (54 to 64) 48 (44 to 52) 0.0003†
Disease duration after onset, days 424 (267 to 959) 380 (243 to 1,169) 466 (303 to 865) 0.772†
Disease duration after diagnosis, days 58 (24 to 269) 43 (19 to 201) 59 (30 to 299) 0.198†
Bulbar onset/spinal onset 15/27 4/18 11/9 0.011‡
Family history (yes/no) 3/39 2/10 1/19 0.603‡
ALSFRS-R 38 (35 to 43) 36 (32 to 43) 39 (35 to 43) 0.397†
Lymphocyte count, /mm3 1,382 (1,096 to 1,819) 1,485 (1,056 to 1,772) 1,253 (1,132 to 1,973) 0.968†
Albumin, g/dL 3.8 (3.7 to 4.2) 4.0 (3.7 to 4.4) 3.8 (3.6 to 4.2) 0.293†
FFM, kg 33.8 (30.0 to 40.6) 39.8 (35.9 to 44.2) 30.0 (24.6 to 33.5) <0.0001†
%Body fat, kg 15.7 (12.9 to 20.6) 15.5 (12.8 to 19.7) 15.8 (13.7 to 20.7) 0.407†
Skeletal muscle index, kg/m2 5.9 (4.8 to 6.4) 6.2 (5.7 to 7.0) 5.0 (4.1 to 6.0) 0.0004†
BEE, kcal/day 1,146 (1,060 to 1,275) 1,232 (1,130 to 1,368) 1,076 (1,039 to 1,191) 0.0024†
REE, kcal/day 1,254 (1,082 to 1,500) 1,474 (1,327 to 1,613) 1,080 (1,049 to 1,228) <0.0001†
RQ 0.84 (0.81 to 0.91) 0.84 (0.81 to 0.91) 0.83 (0.81 to 0.89) 0.404†
REE/FFM 36.6 (34.4 to 41.2) 37.0 (34.8 to 39.7) 34.9 (34.1 to 43.2) 0.855†
ΔREE: REE/BEE 1.07 (0.99 to 1.16) 1.15 (1.08 to 1.26) 0.99 (0.97 to 1.04) <0.0001†
BEE × AF 1,483 (1,372 to 1,623) 1,567 (1,468 to 1,769) 1,376 (1,333 to 1,538) 0.0023†
REE × AF 1,627 (1,378 to 1,906) 1,895 (1,721 to 2,065) 1,394 (1,347 to 1,555) <0.0001†
Shimizu equation 1,660 (1,531 to 1,923) 1,833 (1,579 to 2,091) 1,611 (1,431 to 1,819) 0.031†
%FEV 1.0 80.5 (72.6 to 90.9) 80.6 (70.9 to 89.8) 82.2 (75.5 to 91.9) 0.610†
Tidal volume, L 0.66 (0.52 to 0.90) 0.86 (0.69 to 1.00) 0.58 (0.49 to 0.64) 0.0005†
%FVC 86.1 (65.0 to 97.8) 87.7 (62.9 to 99.5) 86.1 (64.9 to 93.3) 0.793†
Events* (yes/no) 16/26 9/13 7/13 0.758‡
Observation period, days 319 (137 to 440) 270 (97 to 362) 394 (145 to 560) 0.071†
Values are shown as the median (IQR). Bold text indicates statistically significant results. ALS, amyotrophic lateral sclerosis; IQR, 
interquartile range; ALSFRS-R, Revised Amyotrophic Lateral Sclerosis Functional Rating Scale; REE, resting energy expenditure; FFM, 
fat-free mass; BEE, basal energy expenditure; AF, activity factor; %FEV 1.0, percent forced expiratory volume in 1 s; %FVC, percent 
forced vital capacity; BMI, body mass index; RQ, respiratory quotient. * Events were defined as death or tracheostomy. † Mann-Whitney 
U test. ‡ χ2 test.
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Energy Requirements
REE was significantly higher than BEE in all pa-
tients (p < 0.0001) and in men (p < 0.0001) but not in 
women (p = 0.956). Results of comparison of TEE were 
similar because the same active factor was used. The 
values obtained using the Shimizu equation were sig-
nificantly higher than REE × AF in all patients (p = 
0.024) and in women (p < 0.0001) but not in men (p = 
0.317, Fig. 1).
The Bland-Altman plot showed that BEE × AF tended 
to become lower than REE × AF with increased energy 
expenditure: the difference between BEE × AF and REE 
× AF was significant (p < 0.0001, Fig. 2a). The differences 
between the values obtained using the Shimizu equation 
and REE × AF were also significant, but values obtained 
using the Shimizu equation were closer than BEE × AF to 
REE × AF (p = 0.036, Fig. 2b).
Factors Affecting REE or REE/FFM
Single regression analysis was performed to find fac-
tors affecting REE measured by indirect calorimetry. 
Male sex, height, BW, BMI, BEE, FFM, SMI, and tidal 
volume were significantly associated with REE. SMI and 
%FVC were significant factors affecting REE/FFM (Ta-
ble 2).
Development of a Predictive Formula for REE
To develop a predictive formula for REE, the param-
eters BEE, SMI, and tidal volume were tested in a stepwise 
manner. BEE and tidal volume were found to be signifi-
cant factors and the following formula was derived for 
predicting REE in ALS patients not using a respirator: 
REE (kcal/day) = 1.000251 × BEE (kcal/day) + 313.3507 
× tidal volume (L) – 112.0360. The Bland-Altman plot 
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Fig. 1. Comparison of BEE × AF, REE × AF, and values obtained 
from the Shimizu equation. BEE, basal energy expenditure; REE, 
resting energy expenditure; AF, activity factor.
Fig. 2. Bland-Altman plot. REE × AF was compared with values 
given by BEE × AF (a), the Shimizu equation (b), and (c) the pre-
dictive equation derived in this study. BEE, basal energy expendi-
ture; REE, resting energy expenditure; AF, activity factor.
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tained using the Shimizu equation, predicted REE × AF 
was closer to measured REE × AF. There were no signifi-
cant differences between predicted REE × AF and mea-
sured REE × AF (p = 0.985, Fig. 2c).
Event-Associated Factors
Factors associated with the event of death or tracheos-
tomy were low %FVC and low SMI (Fig. 3a, b). Although 
not statistically significant, low BMI or low ALSFRS-R 
tended to be associated with the event of death or trache-
ostomy (Fig. 3c, d).
Discussion
In this study, we ascertained that REE was significant-
ly higher than BEE, indicating hypermetabolism in ALS. 
Hypermetabolism in ALS was negatively and significant-
ly correlated with %FVC and SMI, both of which are as-
sociated with poor prognosis of ALS.
Malnutrition is associated with poor prognosis in ALS, 
and nutritional support via a high calorie diet has im-
proved prognosis [34], especially in rapidly progressive 
patients [35]. Therefore, the accurate calculation of en-
ergy requirement is essential for nutritional manage-
ment. Although using indirect calorimetry to measure 
energy expenditure in individual patients is useful, it is 
not always available in all facilities, so a predictive for-
mula such as the Harris-Benedict equation is commonly 
used. However, this study has shown that the values ob-
tained by BEE (calculated using the Harris-Benedict 
equation) adjusted by AF were significantly lower than 
the values obtained by the REE adjusted by AF. Impor-
tantly, this trend was more prominent in men than in 
women. Hypermetabolism has been reported to be a fac-
tor affecting nutritional status in ALS [24, 36, 37]. In our 
cohort, median ΔREE was 1.07, indicating a 7% increase 
in metabolism. This increase was lower than the increas-
es reported in Europe and North America [36, 38], prob-
ably due to the tendency toward overestimation with the 
Harris-Benedict equation in the Japanese population, es-
pecially in women [39]. Nevertheless, REE was still sig-
nificantly higher than BEE, clearly indicating marked hy-
permetabolism in ALS.
Compared with the Shimizu equation, which is de-
rived from the Harris-Benedict equation and ALSFRS-R 
score, REE × AF showed lower values, and this trend was 
more evident in women than in men. On the other hand, 
Bland-Altman plots showed that BEE × AF values became 
lower than measured REE × AF with increasing energy 
requirement. We performed multiple regression analysis 
to derive a formula for predicting REE and surprisingly 
found that tidal volume, but not ALSFRS-R, is a signifi-
cant factor to be included in the calculation formula. The 
validity of the formula developed in this study needs to be 
examined in the future.
Factors related to body composition, such as sex, 
height, BW, SMI, and tidal volume, were found to be 
Table 2. Regression analysis of factors affecting REE and REE/FFM
All patients (N = 42) Univariate REE HR (95% CI), p value Multivariate REE HR (95% CI), p value Univariate REE/FFM HR (95 %CI), p 
value
Age, years 3.805 (−14.19 to 1.188), 0.095 – −0.065 (−0.226 to 0.096), 0.419
Male = 1, female = 2 178.0 (127.9 to 228.0), <0.0001 – −0.818 (−2.384 to 0.747), 0.296
Height, cm 25.48 (19.90 to 31.06), <0.0001 – −0.099 (−0.306 to 0.107), 0.336
Body weight, kg 20.23 (14.4 3 to 26.02), <0.0001 – −0.129 (−0.303 to 0.044), 0.139
BMI, kg/m2 23.72 (−0.799 to 48.24), 0.057 – −0.302 (−0.835 to 0.230), 0.257
ALSFRS-R 5.047 (−5.392 to 15.48), 0.334 – −0.135 (−0.370 to 0.100), 0.251
BEE, kcal/day 1.161 (0.878 to 1.444), <0.0001 1.002 (0.730 to 1.274), <0.0001 −0.0004 (−0.010 to 0.009), 0.922
FFM, kg 28.49 (22.41 to 34.57), <0.0001 – –
%Body fat 1.255 (−13.72 to 16.23), 0.866 – 0.216 (−0.073 to 0.505), 0.138
SMI, kg/m2 148.9 (98.08 to 199.7), <0.0001 – –2.639 (–3.746 to –1.532), <0.0001
%FEV 1.0 −0.334 (−7.734 to 7.065), 0.927 – 0.112 (−0.033 to 0.258), 0.127
Tidal volume, L 566.8 (310.2 to 823.4), <0.0001 313.3 (133.8 to 492.8), 0.001 −4.567 (−10.59 to 1.460), 0.133
%FVC 1.946 (−1.926 to 5.819), 0.315 – –0.097 (–0.172 to –0.021), 0.013
Bold text indicates statistically significant results. REE, resting energy expenditure; FFM, fat-free mass; HR, hazard ratio; CI, confidence interval; BMI, 
body mass index; ALSFRS-R, Revised Amyotrophic Lateral Sclerosis Functional Rating Scale; BEE, basal energy expenditure; SMI, skeletal muscle index; 
%FEV 1.0, percent forced expiratory volume in 1 s; %FVC, percent forced vital capacity.
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significant factors affecting REE. Further, SMI and 
%FVC were significant factors associated with REE/
FFM as an indicator of metabolic change, showing that 
hypermetabolism occurred in patients with reduced 
muscle mass and %FVC. Previous studies showed that 
the prognosis of ALS is associated with %FVC [12–14], 
BMI [10], and ALSFRS-R score [11, 12]. However, in 
this study, we found a significant link to %FVC alone, 
and not to BMI or ALSFRS-R score. This might be due 
to our relatively small sample size. Nevertheless, our re-
sults indicate that, together with early evaluation of 
BMI or ALSFRS-R, early evaluation of respiratory func-
tions crucial for predicting prognosis. In addition, we 
identified SMI as a novel prognostic factor in the pres-
ent study, suggesting that it can serve as a relatively sen-
sitive index for predicting prognosis. The association 
between loss of muscle mass and prognosis has been 
reported in a variety of diseases [40, 41]. Notably, sar-
copenic obesity is also considered a poor prognostic 
factor [42–44]. This study demonstrated the impor-
tance of assessing muscle mass by measuring body 
composition in ALS, as sarcopenia may be overlooked 
when assessing body weight or BMI alone.
There are some limitations to this study. First, this was 
a retrospective single-center study, so the number of pa-
tients included was small. Hence, the significance of our 
results should be confirmed in a prospective multicenter 
study. Second, our cohort had a relatively lean body type, 
so the results might not be applicable to other popula-





































































































Fig. 3. Cumulative event-free survival. Kaplan-Meier curves depicting cumulative event-free survival, stratified 
by %FVC (a), SMI (b), BMI (c), and (d) ALSFRS-R. Wilcoxon analysis was performed to analyze the data. %FVC, 
percent forced vital capacity; SMI, skeletal muscle index; BMI, body mass index; ALSFRS-R, Revised Amyo-
trophic Lateral Sclerosis Functional Rating Scale; REE, resting energy expenditure.
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is lower than that of ALS patients in Europe and North 
America (23.7–27.1 kg/m2) [36, 45–51] and even low 
compared with that reported in other Asian populations 
(21–22 kg/m2) [52, 53].
Taken together, this study showed that metabolism is 
increased in ALS patients and that the Shimizu equation 
was a better predictive formula for TEE compared with 
BEE × AF. Also, low SMI and low %FVC were shown to 
be significantly associated with hypermetabolism. In ad-
dition to %FVC, which has been reported as a prognostic 
factor, SMI may also be useful as a prognostic indicator.
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